Nabriva Therapeutics PLC reports results for the quarter ended in June - Earnings Summary

Nabriva Therapeutics

05/08/2021 23:02

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted loss of 3 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 35 cents per share.
* Revenue rose 1,592.6% to $8.24 million from a year ago; 
analysts expected $5.99 million. 
* Nabriva Therapeutics PLC's reported EPS for the quarter was a
loss of 3 cents​.
* The mean earnings estimate of analysts had risen by
about 15.4% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Nabriva Therapeutics PLC shares had fallen by 10.4% this
quarter and lost 50.0% so far this year.
* The company reported a quarterly loss of $11.75 million.
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $3.68 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 5 at 10:02 p.m.  ​All
figures in US dollars unless otherwise stated